✦ LIBER ✦

PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC): A UK PERSPECTIVE

✍ Scribed by P Ducournau; G Lewis; A McDonald; DR Millar; E Sabate; S Walzer

Book ID: 119597429
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 95 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)66578-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN26 A COST-EFFECTIVENESS ANALYSIS OF X

PCN26 A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

✍ J Darba; G Restovic; A Ramírez de Arellano 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

EE8 COST EFFECTIVENESS OF CAPECITABINE I

EE8 COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

✍ DR Millar; P Ducournau; A McDonald 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

A phase I trial of vandetanib combined w

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer

✍ Elwyn C. Cabebe, George A. Fisher, Branimir I. Sikic 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 112 KB

EC3 COST-MINIMIZATION ANALYSIS OF CAPECI

EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

✍ G Perrocheau; M Ducreux; M Hebbar; M Ychou; G Lledo; T Conroy; R Faroux; JY Doui 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Cetuximab Plus Capecitabine and Irinotec

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104--A Randomized Trial of the German AIO CRC Study Group

✍ Moosmann, N.; von Weikersthal, L. F.; Vehling-Kaiser, U.; Stauch, M.; Hass, H. G 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

PCN74 A SERVICE EVALUATION TO COMPARE SE

PCN74 A SERVICE EVALUATION TO COMPARE SECONDARY CARE RESOURCE USE BETWEEN XELOX AND FOLFOX-6 REGIMENS IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

✍ DR Millar; P Corrie; M Hill; A Pulfer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB